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Background. Loss of the allograft from chronic allograft
nephropathy and death of the patient from vascular, malignant,
or infective disease are the major problems in renal transplanta-
tion today. Protocol biopsy of the long-term kidney has provided
new data with which to develop strategies for prevention and
treatment of chronic allograft nephropathy.
Methods. Two series of long-term protocol biopsies are re-
viewed. In the first, renal biopsies were obtained at time 0, and
at 3 months and 12 months, and the recipients of the renal allo-
grafts were followed up for up to 15 years. In the second, the kid-
neys of recipients of simultaneous pancreas kidney transplants
were biopsied annually for 10 years, and the results correlated
with clinical events.
Results. Chronic allograft nephropathy is caused by acute
and chronic immune-mediated damage, as well as by chronic
calcineurin inhibitor nephrotoxicity. Both immune and nonim-
mune mechanisms exacerbate pre-existing donor disease and
ischemia-reperfusion injury. Established interstitial fibrosis and
arteriolar hyalinosis lead to progressive glomerular sclerosis
and eventual loss of the graft.
Conclusion. Protocol biopsies have shown that clinical pa-
rameters of renal function underestimate the severity of chronic
graft damage. Strategies for preventing or treating chronic re-
nal allograft dysfunction and subsequent graft loss must better
control rejection and simultaneously avoid nephrotoxicity.
Chronic allograft nephropathy (CAN) is the cause of
a majority of graft failures now that the risk of acute al-
lograft rejection has diminished [1]. Although the issue
is quite hotly debated, it is clear that the reduction in in-
cidence of acute rejection has had little or no effect on
the long-term prognosis of grafts [2]. Patient death from
vascular, malignant, or infective disease and loss of the al-
lograft from chronic allograft nephropathy are the major
problems in renal transplantation today [1, 3].
Understanding the phenomenon of “chronic rejection”
or “chronic allograft nephropathy” is thus central to our
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ability to tackle the long-term attrition of grafts. The kid-
ney has a relatively restricted response to injury, and so a
simple description of the histological appearance at any
particular point in time may not help in understanding
causality. However, data from a number of longitudinal
histological studies are beginning to unravel these rela-
tionships and thus assist not only in understanding the
processes of chronic allograft damage, but also in identi-
fying prevention and treatment strategies.
CLINICAL FEATURES OF CAN
Factors that relate to the donor, transplant surgery,
and the recipient determine the initial function of a re-
nal transplant, which varies widely between patients. The
terms “intercept” and “slope” have been used to describe
the different influences on renal allografts as they de-
teriorate and fail [4]. The kidney from a young living
donor who suffers no early acute rejection may yield an
initial glomerular liltration rate (GFR) of 70 mL/min,
which may rise to 100 mL/min in the early months be-
cause of glomerular hyperfiltration. By contrast, the kid-
ney from an elderly deceased donor with a history of
hypertension and 20% sclerosed glomeruli on the im-
plantation biopsy, which then suffers from significant is-
chemic damage and early rejection, may only achieve a
maximum GFR of 30 mL/min. The “intercept” values are
thus 100 mL/min and 30 mL/min, respectively. Even if the
subsequent “slope” of decline in GFR is 5 mL/min/year
identically for both kidneys, on clinical follow-up they will
appear to behave very differently in the next years. The
GFR will reach 10 mL/min in only 4 years for the dam-
aged kidney, but it will take 18 years for the undamaged
kidney to reach the same level. The pathophysiology of
the “slope” may be the same in the two instances, but the
clinical effect is dramatically different.
The poorly functioning graft will have dropped the ini-
tial serum creatinine level to perhaps only 180 lmol/L.
Within a year, the creatinine will reach 220 lmol/L, but
may have fluctuated between 170 lmol/L and 220 lmol/L
during the year, as the variable influences of acute
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calcineurin inhibitor (CNI) toxicity, hydration status, and
concomitant infections have impacted on the patient.
The alarm will be raised as the creatinine rises from
220 lmol/L to 250 lmol/L or higher, and a biopsy may or
may not be performed. Proteinuria and hypertension will
be noted at this point in the follow-up, and angiotensin-
converting enzyme inhibitors may be commenced. If the
biopsy had been performed, the pathologist would have
reported grade III CAN. A clinical diagnosis of CAN is
determined in the absence of a biopsy, and a series of
therapeutic strategies may be implemented with varying
levels of success.
The younger living donor kidney is regarded as a huge
success with a starting GFR of 100 mL/min. The GFR of
this kidney also falls at a steady 5 mL/min each year, but
there is no impact on the creatinine value, which is stable
between 80 lmol/L and 90 lmol/L. It is only in the 14th
year of the transplant that the creatinine level begins to
cause concern, because the GFR has fallen to 30 mL/min,
and the creatinine is now noticeably higher than it was a
few years ago. The surgeon and physician who performed
the transplant in the patient have retired, and it becomes
apparent to the patient that their care was excellent, be-
cause the kidney only started to deteriorate when the new
physician arrived. The new physician biopsies the kidney,
the pathologist reports grade III CAN, and the young
physician privately blames his predecessors for not diag-
nosing and managing the problem earlier. The chronic
pathologic process has been identical in the two kidneys,
but the impact of the renal functional reserve has differ-
entiated the two clinical courses.
THE PATHOLOGIC FEATURES OF CAN
Classification of renal transplant histology was given
the necessary intellectual and physical impetus through
a series of meetings in Banff [5–8], which focused ini-
tially on acute rejection. “Chronic allograft nephropa-
thy” (CAN) was defined histologically, with those words
deliberately chosen to avoid the implications of etiology
carried by the words “chronic rejection” [5]. However,
Colvin has noted that identification of specific features
can lead to an etiologic assignment in around 60% of all
biopsies [9]: e.g., interstitial fibrosis and tubular atrophy
with nodular arteriolar hyalinosis implying CNI toxicity;
and vascular changes with disruption of the elastica, in-
flammatory cells in the fibrotic intima, and proliferation
of myofibroblasts in the intima implying chronic immune-
mediated rejection.
CAN is defined and graded in the Banff 97 system
[5] by identification of interstitial fibrosis and tubular
atrophy. These features were selected because they are
widespread and relatively reproducible in small tissue
samples. CAN is graded from I to III based on the propor-
tion of the cortical area of the biopsy affected by chronic
interstitial fibrosis and tubular atrophy (grade I = 6%–
25%, II = 26%–50%, III = >50%). Linkage between
the CAN grade and the chronic Banff qualifiers for inter-
stitial fibrosis (ci) and tubular atrophy (ct) is imprecise,
because the overall appearance of the sample is graded
directly for CAN and not indirectly from the severity of its
components. Common usage has lead to the term CAN
being a description and grading of chronic damage to
the graft, whether it has resulted from prior acute re-
jection, calcinerin inhibitor nephrotoxicity, hypertensive
nephrosclerosis, or some other etiology.
Modern biopsy techniques make the acquisition of his-
tology data much safer, with the routine use of ultrasound
localization, 18 G needles, and spring-loaded biopsy guns.
A multicenter European study of 2127 biopsies demon-
strated one attributable graft loss and three direct in-
terventions for bleeding [10]. The risk-benefit ratio for
the individual patient has swung to favor protocol-driven
biopsy schedules rather than simply be event-driven,
which leads to a sound basis for examination of the under-
lying behavior of the disease processes leading to CAN.
LONGITUDINAL HISTOLOGY RESULTS
Our group in Sydney has published two series of pro-
tocol biopsies in which we have addressed the causes and
correlates of CAN, the statistically significant results of
which are reported below. In the first series, biopsies were
obtained at time 0 and at 3 months and 12 months from
recipients of renal allografts. These patients were then
followed up clinically for up to 15 years [11, 12]. In the
second series, recipients of simultaneous pancreas kidney
transplants were biopsied annually for 10 years, yielding
approximately 1000 biopsies from 120 patients [13–17].
The two series have different attributes, especially with
respect to the types and ages of the donors from which
the kidneys were derived. The first series included kid-
neys from deceased and living donors of all ages with a
variety of pre-existing conditions and was able to demon-
strate the correlates and predictive value of early dam-
age. In contrast, the kidneys in the second series were all
transplanted with short ischemia times from donors un-
der 45 years of age, with almost no histological abnormal-
ities on the day 0 biopsy. This series is thus powerfully able
to identify the histological evolution of long-term graft
fibrosis [13] and describe the natural history of CAN in
the kidneys of diabetics receiving simultaneous pancreas
transplants. A strength of the study has proven to be the
unveiling of the intrarenal relationships between fibrosis
and arteriolar and glomerular damage.
PREDICTORS OF 3-MONTH AND 12-MONTH
HISTOLOGY
The 3-month protocol biopsy histology revealed both
chronic and acute changes that were characterized using
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the then-current Banff schema [11, 12]. At 3 months, only
22% of grafts were normal and 54% had CAN grade I,
whereas the remaining 24% already had CAN grade II
or III. The chronic changes were predominantly intersti-
tial fibrosis and tubular atrophy, together with chronic
vascular disease. The statistically significant predictors of
interstitial disease were donor age, prior vascular rejec-
tion, and delayed graft function. Vascular disease was pre-
dicted by donor vascular disease, total cold ischemic time,
and prior vascular rejection. The histology at 12 months
correlated with changes on the 3-month biopsy. Acute
Banff qualifiers in the 3-month biopsy were: interstitial
infiltrate, tubulitis, and vasculitis (i, t, and v, respectively),
each correlated with the relevant chronic changes in the
1-month biopsy (ci, ct, cv). Thus, for each individual pa-
tient, subclinical rejection detected on the 3-month proto-
col biopsy led to the development of CAN by 12 months.
Renal functional decline and ultimate graft survival
were predicted by the 3-month ci and cv scores, as well as
by the presence of proteinuria. Late acute rejection, pre-
sumed in most cases to result from noncompliance, was
also a strong predictor of late graft loss. Indices of cy-
closporine exposure, the presence of hypertension, and
donor and recipient age did not, however, correlate with
outcomes.
LONG-TERM PROTOCOL HISTOLOGY
The second series of protocol biopsies was more exten-
sive than the first. The biopsies were taken from 1987 to
1999 and were performed as part of a long-term study of
the impact of simultaneous pancreas and kidney trans-
plantation in patients with insulin-dependent diabetes
mellitus [13]. The follow-up protocol included measured
GFR, an oral glucose tolerance test, renal transplant
biopsy, and recording of clinical parameters at each time
point. The overall 1-year survival was excellent, with
96% patient survival, 94% kidney survival, and 85% pan-
creas survival. Similarly good results were seen for the
10-year survival of patients (80%), kidneys (77%), and
pancreases (67%) [13]. The average measured GFR of
the surviving kidneys was 61 mL/min at 1 year and
50 mL/min between 6 and 10 years. In the context of these
good results, the pathologic changes were surprising and
disappointing, but correctly predicting graft failure for
several long-term patients between 10 and 15 years.
SUBCLINICAL REJECTION
Subclinical rejection was defined as either border-
line/suspicious or acute subclinical rejection in patients
with stable serum creatinine values at the time of biopsy,
using the histological hallmarks of rejection (Banff i and
t scores) [14]. The frequency of interstitial inflamma-
tion and tubulitis declined exponentially with time after
transplantation; was dependent on the immunosuppres-
sive protocol, being less common with tacrolimus than
cyclosporine, and mycophenolate mofetil than azathio-
prine; and was persistent in only 6% of patients. The im-
pact of both borderline and acute subclinical rejection
was to increase the subsequent incidence of interstitial fi-
brosis and tubular atrophy, mimicking the data in the first
series. Persistent subclinical rejection, proposed as the
definition of true chronic cellular rejection, not only in-
creased graft fibrosis but also reduced the GFR by about
half over 2 years. Chronic inflammation, restricted to ar-
eas of interstitial fibrosis and thus ignored under the Banff
schema, was also seen to correlate with increased fibrosis
in follow-up biopsies.
Immunosuppression was clearly effective in reduc-
ing both subclinical rejection and preventing its seque-
lae, with micro-emulsion cyclosporine (Neoral; Novartis,
Basel, Switzerland) being more effective than the
older formulation (Sandimmune, Novartis); and with
tacrolimus (Prograf, Astellas, Tokyo, Japan) being more
effective than cyclosporine in reducing the density of cel-
lular infiltrate. Mycophenolate mofeil reduced tubulitis,
while the combination of tacrolimus and mycopheno-
late mofetil effectively abolished subclinical rejection by
3 months. Tapering of the corticosteroid dose between
3 and 6 months led to an increase in the prevalence of
subclinical rejection in cyclosporine-treated patients.
INTERSTITIAL FIBROSIS AND TUBULAR
ATROPHY
Mild fibrosis was present in only 5% of implanta-
tion biopsies in this series of young donors selected for
the suitability of the pancreas. Both interstitial fibro-
sis and tubular atrophy increased markedly during the
first year and thereafter accumulated at a slower rate
[15]. Two thirds of the total burden of fibrosis occurred
in the first year and was associated with acute tubular
necrosis, acute rejection, and untreated subclinical re-
jection. Interstitial fibrosis exceeded loss from tubular
atrophy 2-fold in the first year, but thereafter tubuloint-
erstitial injury developed simultaneously. As the level of
mononuclear cell infiltration declined with time as a cause
of fibrosis, the importance of CNI toxicity increased.
Tubulointerstitial damage preceded and correlated with
the degree of glomerulosclerosis observed in subsequent
biopsies. Renal function, as expected, declined in propor-
tion to the amount of fibrosis, from a measured GFR of
65 mL/min in patients with normal biopsies to 59 mL/min
and 44 mL/min with mild and moderate fibrosis, respec-
tively. Once established, tubulointerstitial damage did
not regress in subsequent biopsies. Immunosuppression
considerably modified the degree of damage seen, medi-
ated predominantly through the different impacts of the
drugs on acute, subclinical, and persistent rejection.
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ARTERIOLAR HYALINOSIS AND CNI
NEPHROTOXICITY
CNI nephrotoxicity has been defined histologically
through presence of the characteristic lesions of nodu-
lar arteriolar hyalinosis, striped interstitial fibrosis, and
tubular microcalcification. These lesions were detected
in 100%, 88%, and 79% of patients in this series by
10 years [16]. At 1 year, 54% of patients had two of
these histological hallmarks present, rising to 100% by
10 years. A threshold cyclosporine dose of 5 mg/kg/day
was associated with development of CNI nephrotoxic-
ity within the first 5 years. Although classical striped fi-
brosis and nodular hyalinosis are largely restricted to
CNI nephrotoxicity, diffuse arteriolar hyalinosis, tubu-
lar calcification, and the latter stages of diffuse inter-
stitial fibrosis have a number of potential etiologies. In
this study, arteriolar hyalinosis was correlated with mea-
sures of cyclosporine exposure, including trough lev-
els greater than 200 ng/mL at 3 months and preceding
episodes of acute reversible nephrotoxicity. There was,
however, no correlation with oral glucose tolerance or
glycosylated hemoglobin. Hypertension preceded arteri-
olar hyalinosis and was present in 68% of hypertensive
and 60% of normotensive patients. The appearance of
de novo diffuse arteriolar hyalinosis was thus unrelated
to blood pressure, dyslipidemia, glucose tolerance, or is-
chemia, and was specific for CNI nephrotoxicity. There
were no differences between tacrolimus and cyclosporine
in the histological measures of CNI nephrotoxicity, which
supports data from other studies [18].
GLOMERULOSCLEROSIS
First demonstrated in 1963 [19], transplant glomeru-
lopathy is characterized by enlarged glomeruli, mesangial
matrix expansion, changes in mesangial cells, and splitting
of the glomerular basement membrane. It was uncommon
in our series of unsensitized first graft recipients, as was
evidence for recurrence of diabetic nephropathy. Chronic
and progressive glomerulosclerosis, by contrast, was com-
mon and occurred in two phases [17]. The early phase of
glomerular damage, seen within the first month, was as-
sociated with duration of cold ischemia and acute CNI
nephrotoxicity. The later and more important phase of
progressive glomerulosclerosis occurred after 4 to 5 years,
beyond which time one third of all glomeruli had been
lost. The twin causes of glomerular loss were preced-
ing tubulointerstitial nephritis and arteriolar hyalinosis.
The 1-year Banff chronic interstitial fibrosis score and
prior subclinical rejection correlated with development
of glomerulosclerosis by 5 years. Grafts with no intersti-
tial fibrosis at 1 year also eventually developed glomeru-
losclerosis, but to a lesser intensity. Arteriolar hyalinosis
leading to glomerular ischemia was the second major ex-
planation for glomerular loss. A Banff score of ah2 or
above in one biopsy led to an increase in glomeruloscle-
rosis in the subsequent biopsy. The degree of arteriolar
hyalinosis also correlated strongly with the percentage of
sclerosed glomeruli in the same biopsy, with a 3-fold rise
between biopsies with ah1 and ah3. Glomerulosclerosis
correlated significantly but poorly with GFR, unlike the
much tighter correlation with tubulointerstitial damage.
GFR fell in parallel with the increase in glomeruloscle-
rosis, but underestimated the degree of damage, falling
from 59 mL/min with no glomerulosclerosis to 56 mL/min
with 1% to 20% and 52 mL/min with more than 20% of
glomeruli sclerosed.
CONCLUSION
CAN has two primary causes. First, it results from
immune-mediated damage either from acute severe or
vascular rejection, or from undiagnosed and thus un-
treated subclinical rejection, commonly present early and
uncommonly present persistently in later years. Second,
CAN results from CNI nephrotoxicity, which causes ar-
teriolar hyalinosis and interstitial fibrosis. Both immune
and nonimmune mechanisms exacerbate pre-existing
donor disease and the ischemic insult that all grafts suffer
to a varying extent. The establishment of interstitial fibro-
sis and arteriolar hyalinosis independently and together
causes progressive glomerular sclerosis, which precedes
decline in the GFR. Clinical programs monitor change in
the serum creatinine to detect patients at risk of CAN,
but the protocol biopsy evidence now shows that such
clinical parameters dramatically underestimate the sever-
ity of chronic graft damage. Strategies for intervening to
prevent chronic renal allograft dysfunction and subse-
quent graft loss need to better control rejection and, at
the same time, simultaneously avoid the nephrotoxicity
that we have been living with, and accepting, for the past
20 years.
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